79 results about "Alcohol dependence" patented technology

The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of obsessive, impulsive and compulsive behavioral activities and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the 5-HT3 receptor antagonist ondansetron and a selective dopamine D2 receptor antagonist, such as risperidone or olanzapine, that are sufficient to control a subjects obsessive, impulsive and compulsive behavioral activities. Kits comprising the combination of antagonists for the treatment of addictive disorders such as alcohol dependence are also provided.

The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of alcohol dependence and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the 5-HT3 receptor antagonist ondansetron and the selective dopamine D2 receptor antagonist olanzapine that are sufficient to control a subject's craving for alcohol or other addictive substances. Kits comprising the combination of antagonists for the treatment of addictive disorders such as alcohol dependence are also provided.

The present invention provides for compositions and methods for treating or preventing addictive and compulsive diseases and disorders, particular alcohol-related diseases and disorders, disclosed herein. The GLP activators of the present invention are effective against various alcohol and drug dependency diseases. In accordance with the invention, the present compositions and methods can be used to intercede upstream or downstream in the signal transduction cascade involved in GLP action to treat various alcohol and drug dependency diseases. In one embodiment, the synthesis or release of endogenous GLP can be stimulated. In another embodiment, the endogenous synthesis or release of another molecule active in the cascade downstream from GLP, (e.g., a molecule produced in response to GLP binding to a receptor), can be stimulated. Accordingly, the methods and compositions of the invention are useful for preventing, treating, diagnosing, or monitoring the progression various alcohol and drug dependency diseases disclosed herein.

The present invention relates to (−)-1-(3,4-dichlorophenyl )-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In certain embodiments the methods and compositions of the invention are effective for treating attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, and / or an addictive disorder. In more detailed embodiments, methods and compositions of the invention are provided for treating an alcohol-related addictive disorder, for example alcohol abuse, alcohol dependence, excess alcohol consumption, and / or alcohol withdrawal. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof may be employed within the methods and compositions of the invention in a form or composition that is substantially free of its corresponding (+)-enantiomer.

The invention discloses a make method for an edible flos puerariae de-alcoholic fruitcake, which comprises the following raw materials: 3kg of flos puerariae, 1.5kg of hovenia dulcis thumb, 5kg of rhizoma imperatae, 5kg of rhizoma phragmitis, 3kg of mung bean powder, 2kg of Poria cocos, 3kg of root of kudzu vine, 2kg of fructus galangae, 3kg of phaseolus calcaratus, 3kg of phaseolus calcaratus flower, 1.5kg of ginger, 1.5kg of galangal, 1.5kg of liquorice, 2kg of smoked plum, 3kg of olive, 3kg of mulberry, 30kg of molasses syrup, 10kg of high fructose corn syrup, 13kg of glucose, 23kg of granulated sugar, 1.5kg of pectin, 0.7kg of malic acid, 2.5kg of persimmon frost, 3kg of pericarpium citri reticulatae, 3kg of pericarpium citri reticulatae viride, 10g of peppermint oil and 120g of menthol, wherein the glucose is divided into two parts, wherein one part is 8kg, and the other part is 5kg; and the malic acid is divided into two equal parts. The edible flos puerariae de-alcoholic fruitcake improves a bad habit that strong tea is used for preventing alcoholism and sobering up, so that the kidney is prevented from being damaged. After a user drinks wine, the user is free from the wine smell so as to improve a wine drinking atmosphere. As the edible flos puerariae de-alcoholic fruitcake is eaten usually, the edible flos puerariae de-alcoholic fruitcake has an improving action on people with alcoholic liver, fatty liver and alcohol dependence. The edible flos puerariae de-alcoholic fruitcake has the advantages of high power concentration, small volume and concentrated functions, is convenient to carry and is convenient to eat.

The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.

Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

The invention discloses a naltrexone long-acting sustained-release preparation with no need of coating, which is prepared by naltrexone base-racemic form polylactic acid microspheres via a continuous extrusion forming technology. The preparation adopting a W / O / W solvent volatilization method comprises the following steps: dissolving the mixture of naltrexone base and racemic form polylactic acid microspheres in dichloromethane, adding catalyst, carrying out sonic oscillation to form foremilk, volatilizing solvent, filtering, separating polymer, washing, dehumidifying and drying to obtain microspheres, and performing continuous extrusion to extrude granules. In the invention, addictive is not contained, high molecular materials are absolutely degraded without residue, no coating is needed, the medicine arrangement is even, the in vitro and in vivo release of naltrexone is at a 0-level release speed, the blood concentration is stabilized above 2ng / ml of therapeutic dose, the period of sustaining effective blood concentration can be up to more than 540 to 720 days; and the content of naltrexone base is as high as 55%-80%, the sustained-release preparation can be produced in large scale, for treating rehabilitation long-acting relapse prevention and alcoholic dependence, and for treating and preventing senile dementia, and the like.

The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.

Pharmaceutical compositions are disclosed for the treatment of alcohol or cocaine dependence or addiction, alcohol dependence or addiction, reduction of alcohol withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and an alpha2delta ligand and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

The invention relates to novel drug substance for the treatment of alcohol dependence, pharmaceutical composition, medicament and method for treatment of dependence on using ethyl alcohol containing beverages.The invention provides a drug substance for treating alcohol dependence in human and warm-blooded animals representing substituted 1H-benzimidazoles of the general formula 1 or pharmaceutically acceptable salts and / or hydrates thereofwherein: W represents S or S═0 group; R1 represents one or more substituent selected from hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, optionally substituted azaheterocyclyl; R2 represents hydrogen or optionally substituted C1-C4 alkyl; R3 and R4 independently represent optionally identical substituents selected from hydrogen or optionally substituted C1-C4 alkyl; R5 represents an alkyl substituent selected from hydrogen, optionally substituted C1-C7 alkyl, optionally substituted aryl, optionally substituted heterocyclyl, C1-C4 alkoxycarbonyl, optionally substituted aminocarbonyl.

The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoking cessation maintenance therapy. The invention also includes related pharmaceutical compositions comprising nicotine receptor antagonists and either an anti-depressant or an anti-anxiety drug. Specific combinations of drugs (mecamylamine HCl and bupropion HCl) as well as mecamylamine in combination with certain drug classes (e.g., anti-anxiety drugs and anti-depressants) comprise the pharmaceutical compositions disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.

The present invention relates to nalmefene for use in the treatment of anxiety disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid anxiety disorder. The invention further relates to nalmefene for use in the treatment of an anxiety disorder in said patients.

The present invention provides methods for treating alcohol dependence and preventing relapse in subjects in protracted alcohol abstinence. Also provided are methods for treating subjects suffering from cannabis dependence. Typically, these methods entail administering to the subjects in need of treatment a therapeutically effective amount of gabapentin, an analog of gabapentin, or pharmaceutically acceptable salt thereof.

The invention discloses a novel application of dihydromyricetin, namely an application of dihydromyricetin in preparation of food, health care products or medicines with a hangover alleviating effect.The dihydromyricetin has the advantages that the dihydromyricetin has a good hangover alleviating function, can be used for increasing the expression of hippocampus and neuronal GABAARs a4 subunits,has the effects of resisting alcoholism and alcohol dependence, can also effectively prevent liver reduced glutathione depletion and malondialdehyde increase caused by alcohol, reduces the content oftriglyceride, reduces the fatty degeneration degree of hepatocytes, and has good effects of preventing and treating alcoholic liver injury.

The invention discloses a traditional Chinese medicine for treating alcohol-dependent diseases, which is a decoction made of the following raw materials in weight proportion: 30 lily, 15 curcuma, 10 schisandra, 30 mulberry, 12 citrus aurantium, divine music 30, polygala 12, keel 30, salvia miltiorrhiza 15, oyster 30, uncaria 10, gardenia 10, licorice 10, Yizhiren 30, Alisma 15, mother of pearl 30, calamus 15, soybean yellow roll 50; selected in the present invention Pure natural traditional Chinese medicine raw materials, each component conforms to the regulations of the drug administration law, utilizes the comprehensive effects of various traditional Chinese medicines, has the effect of curing alcohol-dependent diseases, has no chemical sweeteners, and is non-toxic and harmless to the human body; No bitterness, easy to take. After years of clinical observation and selection of cases, 10 days is a course of treatment, 2 times a day, 50ml each time, nearly 1,000 patients have been cured, and it is effective when the body is fully recovered, and the total effective rate is 99%. The medicine of the invention can be widely used in clinical treatment of alcohol-dependent diseases.

The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

This invention relates to quercetin derivative, its preparation, and a pharmaceutical combination, as well as their medical uses for the prevention or treatment of diseases related to 5HT1A receptor or neuron cell damages, including Alzeheimer's disease, drug or alcohol dependence, sleep disorders or panic state; and for delaying senility, improving learning and memory, preventing and treatment of neuron cell damages caused by various kinds of cerebral damages.

The invention relates to the technical field of relieving of alcohol dependence, and particularly relates to a fabrication method of anti-alcohol beverage. The anti-alcohol beverage containing aquilaria sinensis tea fungus gel is prepared by the following procedures: adding tea fungus to fresh aquilaria sinensis leaves and a turnjujube extracting solution and fermenting to prepare tea fungus liquid, and then adding gellan gum to prepare gel particles containing the tea fungus liquid; and adding fruit and vegetable juice prepared from tomato and sea-buckthorn juice and honey after bottling, and sealing. Sterile clean operation is realized in the fabrication process. By adopting the anti-alcohol beverage fabricated by the fabrication method, natural anti-alcohol beverage with significant effects of dispelling the effects of alcohol, quenching thirst, preventing or arresting vomiting, protecting gastric mucosa, and protecting the liver is provided for people.

The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.

A method for treating or preventing a host mammal that exhibits aversive signs and symptoms present during protracted abstinence or extended discontinuation syndromes as seen after cessation of compulsive activity, behaviors, or substance use is disclosed. That method comprises administering to a host mammal in need a pharmaceutical composition containing an aversive sign and symptom lessening amount a compound of Formula I or a pharmaceutically acceptable salt thereof dissolved or dispersed in a physiologically acceptable diluent, and repeating the administration as needed,wherein W, X, Y and Z, R1 and Ar are defined within. Data are provided in rats as host mammals using behavioral models dependent on the CRF1 system: defensive burying, alcohol dependence, cocaine dependence and nicotine dependence. A contemplated method also is useful for inhibiting relapse of such a behavior. A contemplated method also is useful for treating substance-related or substance-induced psychiatric disorders that include aversive signs and symptoms.

The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.

The present invention relates to a method for alleviation, prevention, and treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, aggressive behavior, alcohol dependency, psychoses, and related conditions by administering adatanserin and / or metabolites of adatanserin. The present invention also relates to a method of weight loss by administering adatanserin and / or metabolites of adatanserin.

The present invention provides pharmaceutical compositions for intranasal delivery of a benzodiazepine. The composition may contain a therapeutically effective amount of a benzodiazepine or a pharmaceutically acceptable salt thereof, and a permeation enhancer. The permeation enhancer may be propylene glycol or a Hsieh permeation enhancer. The present compositions have excellent bioavailability. After administration of the present compositions, therapeutically effective plasma levels of the benzodiazepine may be achieved rapidly. The present pharmaceutical composition may be used to treat a patient suffering from anxiety, epilepsy, insomnia, agitation, seizures, muscular disorders, alcohol dependence, and drug withdrawal.